Trial Profile
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2010
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- 03 Jul 2010 New trial record